Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATLANTIS phase III trial of lurbinectedin + doxorubicin versus investigator's choice CAV or topotecan in relapsed small-cell lung cancer
2015-001641-89Phase 3Completed
- Sponsor
- PharmaMar
- Start
- May 2016
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of lurbinectedin, doxorubicin, topotecan, cyclophosphamide and vincristine in small cell lung cancer (SCLC) (2 arms), sponsored by PharmaMar. Primary endpoint: Overall survival. Started May 2016; status: completed.
02
Drugs
lurbinectedindoxorubicintopotecancyclophosphamidevincristine
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2015-001641-89.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001641-89.